Phase 1Completed
Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
A Phase 1, Multiple-Dose, Open-Label, Randomized, Crossover Study in Healthy Subjects to Assess the Effect of Pioglitazone (PGZ) on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC) and the Effect of CVC on the PK of PGZ
- Sponsor
- Tobira Therapeutics, Inc. (Industry)
- Enrollment
- 20 enrolled
- Conditions
- Healthy
- Interventions
- Cenicriviroc; Pioglitazone
- Ages
- adults
- Registry
- NCT02342067
Full record on ClinicalTrials.gov
From the registry
A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate the PK of PGZ administered with and without CVC.
Primary outcomes
- Pharmacokinetic Assessment of CVC, as measured by Cmax, Cmin and AUC
- Pharmacokinetic Assessment of PGZ, as measured by Cmax, Cmin and AUC
History
Last registry update
Study completion
Primary completion
Registered
Started